Linerixibat

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

9 competitors in Pruritus

VYNE5mg Serlopitant Tablets

Phase 3

VYNEPlacebo Tablets

Phase 3

VYNE5 mg Serlopitant Tablets

Phase 2

CARAPart A: Placebo

Phase 2

CARAdifelikefalin 2.0 mg

Phase 2

View Full Landscape

Drug Information

Target Indication

Pruritus

Clinical Trial

NCT04950127

Last updated: 2/5/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Lynavoy

Treatment of cholestatic pruritus in adult patients with primary biliary cholangitis.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

FluoridePhase 3

Dental Caries

Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3

Haemophilus Influenzae Type b

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts